Collegium Pharmaceutical (NASDAQ:COLL) Sets New 52-Week Low – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $25.47 and last traded at $25.70, with a volume of 1122273 shares traded. The stock had previously closed at $25.98.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Piper Sandler reissued a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Weiss Ratings cut Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Needham & Company LLC cut their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $52.60.

Collegium Pharmaceutical Price Performance

The firm has a market capitalization of $919.06 million, a P/E ratio of 22.77 and a beta of 0.73. The stock’s 50 day simple moving average is $34.30 and its 200 day simple moving average is $36.39. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the previous year, the firm posted $1.68 earnings per share. The company’s revenue was up 6.3% on a year-over-year basis. As a group, analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. BlackRock Inc. bought a new position in Collegium Pharmaceutical during the 2nd quarter worth about $196,972,000. Rubric Capital Management LP boosted its position in Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Vanguard Group Inc. grew its stake in Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth approximately $77,743,000. Finally, Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock worth $60,358,000 after purchasing an additional 377,073 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.